1. The Defendant’s KRW 35,500,000 as well as the Plaintiff’s annual rate of KRW 5% from February 23, 2016 to September 12, 2018.

1. Basic facts

A. A. On July 4, 2005, the Plaintiff entered into a contract with the Defendant, the insured, and the beneficiary (other than death) with the following terms: (a) cancer diagnosis allowances of KRW 30,00,000, cancer surgery allowances of KRW 5,000,000; (b) cancer hospitalization allowances of KRW 100,000 per day exceeding 3 days when hospitalized treatment for more than 4 days; and (c) 30,000 per day per day for hospitalization of a disease (hereinafter “instant insurance”).

B. B was hospitalized in C Hospital located in Seongbuk-gu, Sungnam-si on August 23, 2015, and was hospitalized in the workplace 28th of the same month (hereinafter “instant species”), and was hospitalized in the hospital for eight days until the 30th of the same month.

C. After conducting the organizational inspection of the species of this case, the medical doctor D of the above hospital, E prepared a pathology report stating that “in 1 phase of neurendocris t, G1), size 0.6cm x 0.4cm x 0.4cm x 0.4cm x 0.4cm x 0.4cm x 0.4cm x m from the point of view to the point of view, mucosa from the Bank, mucosa from the Bank, mucosa to the point of view to the point of view, etc.”

After that, on September 4, 2015, the clinical doctor F, the main doctor of B, prepared a diagnosis report on September 4, 2015, stating the final medical doctor B’s name as “workplace malicious life (C20).”

Article 6 of the terms and conditions of the insurance contract of this case, "Ciam" refers to a disease (attached Table 8) classified as malicious life in the Korean Standard Disease and Death Classification of the fourth Amendment, which is classified as malicious life.

’, ‘암의 진단확정은 해부병리 또는 임상병리의 전문의사 자격증을 가진 자에 의하여 내려져야 하며, 이 진단은 조직(fixed tissue)검사 또는 미세침흡인검사(fine needle aspiration biopsy) 또는 혈액(hemic system)검사에 대한 현미경 소견을 기초로 하여야 하나, 상기의 병리학적 진단이 가능하지 않을 때에는 암에 대한 임상학적 진단이 암의 증거로 인정된다'고 규정하고 있다....